INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH JAK-INHIBITORS COMPARED TO BDMARDS: DATA FROM AN INTERNATIONAL COLLABORATION OF REGISTRIES (THE "JAK-POT" STUDY)

被引：2
|
作者：
Aymon, R. [1 ]
Mongin, D. [1 ]
Bergstra, S. A. [2 ]
Choquette, D.
Codreanu, C. [3 ,4 ]
Cordtz, R. L. [5 ]
Diederik, D. C. [6 ]
Dreyer, L. [5 ]
Elkayam, O. [7 ]
Huschek, D. [8 ]
Hyrich, K. [9 ]
Iannone, F. [10 ]
Inanc, N. [11 ]
Kearsley-Fleet, L.
Kvien, T. K. [12 ]
Leeb, B. [13 ]
Lukina, G. [14 ]
Nordstrom, D. [15 ]
Onen, F. [16 ]
Pavelka, K. [17 ]
Pombo-Suarez, M. [18 ]
Provan, S. Aarrestad
Rodrigues, A. M. [19 ]
Rotar, Z. [20 ,21 ]
Strangfeld, A. [8 ]
Verschueren, P.
Zavada, J.
Courvoisier, D. [1 ]
Finckh, A. [1 ]
Lauper, K. [1 ]
机构：
[1] Geneva Univ Hosp, Div Rheumatol, Geneva, Switzerland
[2] LUMC, Rheumatol, Leiden, Netherlands
[3] CHUM, Inst Rech Rhumatol, Montreal, PQ, Canada
[4] Univ Med, Ctr Rheumat Dis, Bucharest, Romania
[5] Aalborg Univ Hosp, Rheumatol, DANBIO, Aalborg, Denmark
[6] Vrije Univ Brussels, Dept Publ Hlth, Biostat & Med Informat Res Grp, Brussels, Belgium
[7] Tel Aviv Univ, Rheumatol, Tel Aviv, Israel
[8] DRFZ, Programme Area Epidemiol, Berlin, Germany
[9] Univ Manchester, Ctr Epidemiol Versus Arthrit, Manchester, Lancs, England
[10] Univ Hosp Bari, GISEA, Rheumatol, Bari, Italy
[11] Marmara Univ, Sch Med, Rheumatol, Istanbul, Turkiye
[12] Diakonhjemmet Hosp, Ctr Treatment Rheumat & Musculoskeletal Dis REMED, Oslo, Norway
[13] BioReg, Vienna, Austria
[14] AS Loginov Moscow Clin Sci Ctr, VA Nasonova Res Inst, Rheumatol, Moscow, Russia
[15] Helsinki Univ Hosp, ROB FIN, Helsinki, Finland
[16] Dokuz Eylul Univ, Fac Med, Dept Internal Med, Div Rheumatol, Izmir, Turkiye
[17] Inst Rheumatol, Rheumatol, Prague, Czech Republic
[18] Hosp Clin Univ, Rheumatol, Santiago De Compostela, Spain
[19] Univ Nova Lisboa, Inst Med Mol, NOVA Med Sch,CHRC, Rheumatol Res Unit,Rheuma Pt,Soc Portuguesa Rheum, Lisbon, Portugal
[20] Univ Med Ctr Ljubljana, Ljubljana, Slovenia
[21] Univ Ljubljana, Rheumatol, Ljubljana, Slovenia
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷
关键词：
Disease-modifying drugs (DMARDs); Safety; Real-world evidence;
D O I：
10.1136/annrheumdis-2023-eular.660
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
OP0219
引用
收藏
页码：143 / 145
页数：3
相关论文
共 34 条
  • [21] Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism with JAK Inhibitors versus TNF Inhibitors in Rheumatoid Arthritis Patients: A Systematic Review and Meta-Analysis
    Partalidou, Styliani
    Patoulias, Dimitrios
    Deuteraiou, Kleopatra
    Avgerou, Paraskevi
    Kitas, George
    Tzitiridou-Chatzopoulo, Maria
    Dimitroulas, Theodoros
    MEDITERRANEAN JOURNAL OF RHEUMATOLOGY, 2024, 35 (01):
  • [22] COMPARISON OF MAJOR CARDIOVASCULAR AND THROMBOEMBOLIC EVENTS IN SAFETY REPORTS BETWEEN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH JAK INHIBITORS VERSUS ANTI-TNF: RESULTS FROM VIGIBASE
    Montastruc, F.
    Flumian, C.
    Degboe, Y.
    Constantin, A.
    Ruyssen-Witrand, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 178 - 179
  • [23] Adverse events, clinical considerations and management recommendations in rheumatoid arthritis patients treated with JAK inhibitors (vol 14, pg 945, 2018)
    Atzeni, F.
    Talotta, R.
    Nucera, V
    Marino, F.
    Gerratana, E.
    Sangari, D.
    Masala, I. F.
    Sarzi-Puttin, P.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2018, 14 (11) : IX - IX
  • [24] Choosing the right score: the critical role of disease activity metrics in RA treatment outcomes with JAK and IL-6 inhibitors - an international multi-register study from the JAK-pot collaboration
    Kim, Lauper
    Emilie, Laugt
    Denis, Mongin
    Romain, Aymon
    Denise, Choquette
    Catalin, Codreanu
    Florenzo, Iannone
    Tore, Kvien K.
    Burkhard, Leeb
    Galina, Lukina
    Dan, Nordstrom
    Karel, Pavelka
    Sella, Provan
    Ana, Rodrigues
    Ziga, Rotar
    Prodromos, Sidiropoulos
    Axel, Finckh
    Delphine, Courvoisier S.
    SWISS MEDICAL WEEKLY, 2024, 154 : 20S - 20S
  • [25] SYSTEMATIC REVIEW OF REAL-WORLD DATA: ASSESSING CANCER, MAJOR ADVERSE CARDIOVASCULAR EVENTS, VENOUS THROMBOEMBOLISM, INFECTION, AND MORTALITY RISK ASSOCIATED WITH JAK INHIBITORS IN RHEUMATOID ARTHRITIS PATIENTS IN THE UNITED STATES
    Bazzazzadehgan, S.
    Gandy, C.
    Bruera, S.
    Huang, Y.
    VALUE IN HEALTH, 2024, 27 (06) : S161 - S161
  • [26] EFFECTS OF IL6 INHIBITORS ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN RHEUMATOID ARTHRITIS PATIENTS: A SYSTEMATIC REVIEW WITH META ANALYSIS
    Marais, C.
    Hua, C.
    Filhol, E.
    Flaisler, F.
    Lukas, C.
    Morel, J.
    Gaujoux-Viala, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 626 - 626
  • [27] Impact of age and cardiovascular risk factors on the incidence of adverse events in patients with rheumatoid arthritis treated with Janus Kinase inhibitors: data from a real-life multicentric cohort
    Gentileschi, Stefano
    Gaggiano, Carla
    Damiani, Arianna
    Coccia, Carmela
    Bernardini, Pamela
    Cazzato, Massimiliano
    D'Alessandro, Francesco
    Vallifuoco, Giulia
    Terribili, Riccardo
    Bardelli, Marco
    Baldi, Caterina
    Cantarini, Luca
    Mosca, Marta
    Frediani, Bruno
    Guiducci, Serena
    CLINICAL AND EXPERIMENTAL MEDICINE, 2024, 24 (01)
  • [28] JAK-inhibitors and risk on serious viral infection, venous thromboembolism and cardiac events in patients with rheumatoid arthritis: A protocol for a prevalent new-user cohort study using the Danish nationwide DANBIO register
    Faquetti, Maria Luisa
    Vallejo-Yague, Enriqueta
    Cordtz, Rene
    Dreyer, Lene
    Burden, Andrea M.
    PLOS ONE, 2023, 18 (07):
  • [29] Assessment of Interstitial Lung Disease in Rheumatoid Arthritis Patients Treated with JAK Inhibitors: A National Multicenter Observational Study from the MAJIK-SFR Registry
    Triboulet, Felicien
    Juge, Pierre-Antoine
    Truchetet, Marie-Elise
    Pham, Thao
    Roux, Nicolas
    Flipo, Rene-Marc
    Leske, Charles
    Roux, Christian
    Seror, Raphaele
    Basch, Andre
    Brocq, Olivier
    Chazerain, Pascal
    Coury-Lucas, Fabienne
    Damade, Richard
    Dernis, Emmanuelle
    Gottenberg, Jacques-Eric
    Ramon, Andre
    Ruyssen-Witrand, Adeline
    Salmon, Jean-Hugues
    Shipley, Emilie
    Tournadre, Anne
    Prati, Clement
    Dieude, Philippe
    Avouac, Jerome
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 4525 - 4528
  • [30] BIOLOGICS AND JAK INHIBITORS DECREASE MAJOR CARDIOVASCULAR EVENTS (MACE) IN IBD PATIENTS. DATA FROM A LARGE NATIONAL COHORT. IS IT THE MECHANISM OF THE DRUG OR CONTROL OF DISEASE?
    Patel, Paraj
    Iqbal, Omair
    Mohananey, Divyanshu
    Bajwa, Saffia
    Khani, Masoud
    Luo, Jake
    Stein, Daniel J.
    Hashash, Jana G.
    Mansoor, Emad
    Cross, Raymond K.
    Sinh, Preetika
    GASTROENTEROLOGY, 2024, 166 (05) : S172 - S172
1234